Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005
description
Transcript of Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005
![Page 1: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/1.jpg)
Yassir EL-AZIZI
Literature meeting A. Charette group
15 Feb. 2005
Statins Family: Cholesterol-Lowering Drugs
![Page 2: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/2.jpg)
• Statin drugs constituted 6% of the total annual sale of the top 200 drugs in
1999, worth $125 billion in the USA.
Statins Family: Cholesterol-Lowering Drugs
MAUREEN ROUHI, ‘CHIRAL CHEMISTRY’, C&EN News, 2004, 82, Number 24, 47-62
![Page 3: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/3.jpg)
•Introduction
•Cholesterol biosynthesis
•The missing members of the family
•Merck reduction of complexity of natural statins
•Synthetic Statins
• Exemple of industrail synthesis: Lescol
Statins Family: Cholesterol-Lowering Drugs
OUTLINE
![Page 4: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/4.jpg)
OH
O
OHO
O
Lovastatinmevinolin, monacolin K, Mevacor®, Merck
First to be marketed in 1987
OH
O
OHO
O
O
HO
H
OH
HO
O
O O-, Na+
Pravastatineptastatin, Pravachol®,
Bristol-Myers Squibb/Sankyo
SimvastatinSynvinolin, Zocor®, Merck
OH
O
OHO
O
Mevastatincompactin, ML-236B, CS-500
METKINEN OYBalkanpharma-Razgrad AD
OHH
O
OHO
Monacolin J
H
O
OHO
Monacolin L
OH
O
OHO
OO
Monacolin X
OH
O
OHO
OOH
Monacolin M
H
H
Statins Family: Cholesterol-Lowering Drugs
O
ONa
N
F
OH OH
Lescol® (fluvastatin sodium)
NOVARTIS
O
OH
O
N
OHN
F
Lipitor®Atovarstatin
Pfizer
O
OH
O
N
N
F
NSO
O
CO2NaOHOH
N
H3CO
F
Baycol®Cerivastatin sodium
Bayer
Crestor®RosuvastatinAstraZeneka
FDA approval in Aug. 2003
CO2-
OHOH
N
F
2
Ca2+
pitavastatin (NK 104)
phase III clinical trials
![Page 5: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/5.jpg)
OH
O
OHO
O
Lovastatinmevinolin, monacolin K, Mevacor®, Merck
First to be marketed in 1987$389.5m
FERMENTATION
OH
O
OHO
OO
HO
H
OH
HO
O
O O-, Na+
Pravastatineptastatin, Pravachol®,
Bristol-Myers Squibb/SankyoFDA approval in 1996
$1.18bOXIDATION FROM Mevastatin
SimvastatinSynvinolin, Zocor®, Merck
FDA approval in 1998$2.3b
ESTER MODIFICATION FROM LOVASTATIN
OH
O
OHO
O
MevastatinCompactin®, ML-236B, CS-500
SANKYOMETKINEN OY
Balkanpharma-Razgrad AD
OHH
O
OHO
Monacolin J
H
O
OHO
Monacolin L
OH
O
OHO
OO
Monacolin X
OH
O
OHO
OOH
Monacolin M
H
H
FERMENTATION
Statins : Natural and Natural-like structures
![Page 6: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/6.jpg)
R1
R2
H
O
OHO
common main polyketide portion
hexahydro naphthalene ring system
R1= H, OH, O
O
O
O
O
OO
O
OOH
, , ,
R2= H, CH3, OH
‘…the mechanism involved in the control of endogenous cholesterol levels by statins makes these molecules suitable for therapeutic use…, Different
types of statins are currently available: the natural statins obtained directly by fermentation, and the semi-synthetic and synthetic statins . Cerivastatin,
a fully synthesized statin approved in the United States in 1997, has been employed until the recent withdrawal from the market. ’ *
Mini reviewManzoni* M, Rollini M., ‘Biosynthesis and biotechnological production of statins
by filamentous fungi and application of these cholesterol-lowering drugs’, Appl. Microbiol. Biotechnol. 2002 Apr.;58(5):555-64.
Statins : Natural and Natural-like structures
![Page 7: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/7.jpg)
•Introduction
•Cholesterol biosynthesis
•The missing members of the family
•Merck reduction of complexity of natural statins
•Synthetic Statins
• Exemple of industrail synthesis: Lescol
Statins Family: Cholesterol-Lowering Drugs
OUTLINE
![Page 8: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/8.jpg)
+ HSCoA
H2CC
CH3HO
CH2C
O O
C SCoA
O
H2CC
CH3HO
CH2C
O O
H2C OH
2NADP+
2NADPHHMG-CoA
mevalonate
HMG-CoA Reductase
5-pyrophosphomevalonateisopentenyl pyrophosphate
geranyl pyrophosphatefarnesyl pyrophosphate
squalene 2,3-oxidosqualene
The biosynthesis of cholesterol and isoprenoids (a group of compounds responsible for cell fluidity and cell proliferation)The biosynthesis of cholesterol and isoprenoids (a group of compounds responsible for cell fluidity and cell proliferation)
The Mevanolate Pathway: Cholesterol Biogenesis
HOHO
19 steps
Lanosterol Cholesterol
OH
HO
O O-
Binding site of the enzyme
HMG-CoA Reductase like inhibior
![Page 9: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/9.jpg)
OH
O
OHO
O
Lovastatinmevinolin, monacolin K, Mevacor®, Merck
OH
O
OHO
O
O
HO
H
OH
HO
O
O O-, Na+
Pravastatineptastatin, Pravachol®,
Bristol-Myers Squibb/Sankyo
SimvastatinSynvinolin, Zocor®, Merck
OH
O
OHO
O
Mevastatincompactin, ML-236B, CS-500
METKINEN OYBalkanpharma-Razgrad AD
OHH
O
OHO
Monacolin J
H
O
OHO
Monacolin L
OH
O
OHO
OO
Monacolin X
OH
O
OHO
OOH
Monacolin M
H
H
Manzoni M, Rollini M., ‘Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs’, Appl. Microbiol. Biotechnol. 2002 Apr.;58(5):555-564.
Natural statins
![Page 10: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/10.jpg)
•Introduction and problematic
•Cholesterol biosynthesis
•The missing members of the family
•Merck reduction of complexity of natural statins
•Synthetic Statins
• Exemple of industrail synthesis: Lescol
Statins Family: Cholesterol-Lowering Drugs
OUTLINE
![Page 11: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/11.jpg)
Total synthesis of natural and natural-like statins
R1
R2
H
O
OHOcommon main polyketide portion
Hexahydro or Octahydro naphthalene ring system Hexaline or octaline
R1= H, OH, O
O
O
O
O
OO
O
OOH
, , ,
R2= H, CH3, OH
![Page 12: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/12.jpg)
Synthetic statins, The missing members of the family…
Review: Rosen, Terry; Heathcock, Clayton H.. ‘The synthesis of mevinic acids’. Tetrahedron (1986), 42(18), 4909-51.
Synthetic studies
1. Danishefsky, S.; Kerwin, J. F., Jr.; Kobayashi, S. J. Am. Chem. Soc. 1982, 204, 358.2. Funk, R. L.; Zeller, W. E. J. Org. Chem. 1982,47, 180. 3. Deutsch, E. A.; Snider, B. B. J. Org. Chem. 1982, 47, 2682.4. Prugh, J. D.; Deana, A. A. Tetrhedron Lett. 1982,23, 281.5. Yang, Y.-L.; Falck, J. R. Tetrahedron Lett. 1982, 23,4305.6. Heathcock, C. H.; Taschner, M. J.; R a n , T.; Thomas, J. A.; Hadley, C. R.; Popjak, G. Tetrahedron Lett.
1982, 23,4747. 7. Lee, T.-J.; Holtz, W. J.; Smith, R. L. J. Org. Chem. 1982,47,4750. MERCK8. Anderson, P. C.; Clive, D. L. J.; Evans, C. F. Tetrahedron Lett. 1983, 24, 1373. 9. Kuo, C. H.; Patchett, A. A,; Wendler, N. L. J. Org. Chem. 1983, 48, 1991. 10. Deutsch, E. A,; Snider, B. B. Tetrahedron Lett. 1983, 24, 3701. 11. Funk, R. L.; Mossman, C. J.; Zeller, W. E. Tetrahedron Lett. 1984, 25, 1655. 12. Majewski, M.; Clive, D. L. J.; Anderson, P. C. Tetrahedron Lett. 1984, 25, 2101. 13. Prasad, K.; Repic,O. Tetrahedron Lett. 1984,25, 2435. NOVARTIS14. R a n , T.; Taschner, M. J.; Heathcock, C. H. J. Org. Chem. 1984, 49, 3994. 15. Rosen, T.; Taschner, M. J.; Heathcock, C. H. J. Org. Chem. 1985, 50, 1190. 16. Burke, S. D.; Saunders, J. 0.; Oplinger, J. A.; Murtiashaw, C. W. Tetrahedron Lett. 1985, 26, 1131. 17. Guindon, Y.; Yoakim, C.; Bernstein, M. A,; Morton, H. E. Tetrahedron Lett. 1985, 26, 1185. 18. Kozikowski, A. P.; Li, C.3. J. Org. Chem. 1985, 50, 778.
![Page 13: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/13.jpg)
Deutsh and Sinder approach to Hexaline system
O
O
.
O
O
OEtEtO
0.5% BHT, benzene, sealed tube.150°C-2h
Excusively
O
O
.
EtO
OH
O OEt
OO OEt
BrPGO
1-Base-catalyzed isomerizationgKOtBu,tBuOH, 12 h, 40 °C, 50%2-[O]
Deutsch, E. A.; Snider, B. B., J. Org. Chem. 1982, 47, 2682.
OH
O
OHO
O
(+) Compactin
![Page 14: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/14.jpg)
Heatcock approach to the Octaline system, Total synthesis of (+) Dihydromevinolin
OH OOAlkylation DA
OO
OCl
Zeller intermediate
OO
3Endo
2Exo
OH
O
OHO
O
(+)Dihydro Mevinolin
OH OOAlkylation DA
OO
OCl
Zeller intermediate
OO
6Endo
1Exo
Re Face of the dienophile
Hecker,S.; Heathcock, C. H. J. Am. Chem. Soc. 1986, 108, 45861.
![Page 15: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/15.jpg)
Heatcock approach to Octaline system, Total synthesis of (+) Dihydromevinolin
OO
OO
1-DA2-MethylCuprate
O O
MeCuprate Axial attack
![Page 16: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/16.jpg)
OO 1-TsNHNH2
2-BuLi
Shapiro reaction
OH1-H2/ Lindlar
2-Ac2O3-m-CPBA4-BF3
OAc
HO
O3
OAc O
HO
OAc O
HO
DBU
OAcOH
HO
LiAl(tBuO)3OH
OH
H
1-TsNHNH22-BuLi
Shapiro reaction
OHO
H
OMe
PhO
1-Acylation
2- separation
O O
H
O
1-Acylation2- selective saponification3- swern oxydation
O
H
OO
O OH
(+) dihydro-mevanolin1-Wittig2- 3,4 hydrogenation with Et3SiH, (PPH3)3RhCl3- desillylation4-cetone reduction5-Lactonisation
MeO2CO
OSiR3
(MeO)3P
95:5
Heatcock approach to Octaline system
Review: Rosen, Terry; Heathcock, Clayton H.. ‘The synthesis of mevinic acids’. Tetrahedron (1986), 42(18), 4909-51.
![Page 17: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/17.jpg)
•Introduction and problematic
•Cholesterol biosynthesis (what can we learn from a biochemical process?)
•The missing members of the family
•Merck reduction of complexity of natural statins
•Synthetic Statins
• Exemple of industrail synthesis: Lescol
Statins Family: Cholesterol-Lowering Drugs
OUTLINE
![Page 18: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/18.jpg)
• New drug design approaches are geared towards making lovastatin analogs that will have longer interaction with the enzyme –increase duration of drug occupancy of active site.
• Structural modification: (Lee, et. al. 1982, Merck & Co)
• Structural modification and simplification: (Hoffman*, Stokker**, et. al. 1985, Merck & Co)
• suppression of the hexahydro-naphtaline system
• Progress toward the introduction of the (3 ,5-Disubstituted [ l, l’-biphenyl] system
Semi- synthetic statins, Modifications of Lovastatin
ClCl
F
O
HO O
HO
O
H
OO
O OH
LOVASTATIN
![Page 19: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/19.jpg)
Synthetic statins, Hoffman- Stokker Modifications I
Cl
Cl
O
OHO
Hoffman, Stokker et al, J. Med. Chem. 1986, 28, 347-358
![Page 20: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/20.jpg)
Synthetic statins, Hoffman- Stokker Modifications II
Hoffman, Stokker, J. Med. Chem. 1986,29, 170-181
ClCl
F
O
HO O
100 (+)
![Page 21: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/21.jpg)
•Introduction and problematic
•Cholesterol biosynthesis (what can we learn from a biochemical process?)
•The missing members of the family
•Merck reduction of complexity of natural statins
•Synthetic Statins
• Exemple of industrail synthesis: Lescol
Statins Family: Cholesterol-Lowering Drugs
OUTLINE
![Page 22: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/22.jpg)
Semi- synthetic statins
O
ONa
N
F
OH OH
Lescol® (fluvastatin sodium)
NOVARTIS
O
OH
O
N
OHN
F
Lipitor®Atovarstatin
Pfizer
O
OH
O
N
N
F
NSO
O
CO2NaOHOH
N
H3CO
F
Baycol®Cerivastatin sodium
Bayer
Crestor®RosuvastatinAstraZeneka
FDA approval in Aug. 2003
F
Cl
Cl
O
OHO
O
OHO
O
OHO
Cl
Cl
O
OHO
O
OHO
2 145 3
![Page 23: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/23.jpg)
Statins Family: Common side chain
R
O
OHO
OH
OOHOHR
1,3 syn diolAbsolute configuration
(3R, 5S)
Enzymatic and chemo-enzymatic approach
OH
OOOHR
Chelation-Controlled Reduction: Stereoselective Formation of syn-1,3-Diols
Chemo and stereoselective epoxyde reduction
OH
OOHR
O
OHIodolactonization
(...)
![Page 24: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/24.jpg)
R H
O+
BR
OH
R
O
O
R
O
O
R
O
O
OR
O
O
OH
(PhSe)2/ NaBH4
AcOH/ EtOH
H2O2/NaOH
MeOH
Grubbs cat.,Ist generation
Acylation
92-96% ee
[O]
R= PhCH2CH2- PhCH=CH- PhCH2OCH2-
O
H
R
H
HO
O
OH
Statins side chain, H. C. Brown approach
Yields:
•Allylboration with (-)-B-allyldiisopinacocamphenylborane 71-76%•Esterification 80% •RCM up to 84%•Epoxydation 86%•1,3-reduction of the epoxyde 87% (Miyashita conditions,ee up to 92%, 99% after recrystallization)
‘It is believed that this reduction proceeds via the formation of PhSeH’
(a) M. Venkat Ram Reddy, Herbert C. Brown*, P. Veeraraghavan Ramachandran*, J. Organomet. Chem. 624 (2001) 239–243.(b) P. Veeraraghavan Ramachandran*, Kamlesh J. Padiya, Vivek Rauniyar, M. Venkat Ram Reddy, Herbert C. Brown*, J. Fluorine Chem. 125 (2004) 615–620.
O
O
OHHO
![Page 25: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/25.jpg)
Regioselective 1,3 reduction of epoxyde
R
O
O
O
Na+,Ph(BR3)Se-
R
O
O
OB(R3)-, Na+
SePh
Na+,Ph(BR3)Se-
R
O
OB(R3)-, Na+
OB(R3)-, Na+
2 EtOH
2 Na+,[BR3(EtO)]-
R
O
O
OH
M. Miyashita, T. Suzuki, M. Hoshino, A. Yoshikishi, Tetahedron, 53, 12469
![Page 26: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/26.jpg)
Statins Family: Common side chain
R
O
OHO
OH
OOHOHR
1,3 syn diolAbsolute configuration
(3R, 5S)
Enzymatic and chemo-enzymatic approach
OH
OOOHR
Chelation-Controlled Reduction: Stereoselective Formation of syn-1,3-Diols
Chemo and stereoselective epoxyde reduction
OH
OOHR
O
OHIodolactonization
(...)
![Page 27: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/27.jpg)
Statins side chain, Narasaka(84), Prasad(87), Ghosh(2002) approach
O
O
OHHO
OO
CHO+
NO2
OTIPS
NO2
OH
OO OTIPS
OTIPSNO2O
O
1-DBU, CH3CN, 83%;2-CuCl, DCC, CH3CN, 87%;
OTIPS
OO
O
1-Zn, HOAc, THF 2-NaHSO3, EtOH-H2O 90%
OTIPSOHO
O
LiI, LAH, Et2O, -78°C
yield 93%syn: anti > 99:1
OHOBnO
O
OOO
OH
OH
1- NaH, BnBr, TBAI, THF2-TBAF, THF, 76%3-NaIO4, RuCl3.3H2O, CCl4-CH3CN-H2O,
1-p-TsOH, CH2Cl2, 65%
2-H2, Pd(OH)2,, EtOAc, 85%
(a) Arun K. Ghosh* and Hui Lei, ‘Chelation-Controlled Reduction: Stereoselective Formation of syn-1,3-Diols and Synthesis of Compactin and Mevinolin Lactone’, J. Org. Chem., 2002, 67, 8783-8788.
(b) Narasaka*, K.; Pai, F., Tetrahedron 1984, 40, 2223.(c) Chen, K.-M.; Hardtmann, G. E.; Prasad*, K.; Repic*, O.; Shapiro, M., Tetrahedron Lett. 1987, 28, 155. (Novartis)
,
![Page 28: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/28.jpg)
Statins side chain, Narasaka(84), Prasad(87), Ghosh(2002) approach
OTIPS
OO
O
Li H
OR
OO
O
Li
R= Bn, CHPh2, Tr, TIPS
OROO
O
Li Li
Li
syn:anti= 2.4:1; 7.5:1;11.5:1;99:1
OBnOO
O
Li
OBn
OO
O
Li
syn:anti= 2.4:1
Arun K. Ghosh* and Hui Lei, , J. Org. Chem., 2002, 67, 8783-8788.
,
![Page 29: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/29.jpg)
Statins Family: Common side chain
R
O
OHO
OH
OOHOHR
1,3 syn diolAbsolute configuration
(3R, 5S)
Enzymatic and chemo-enzymatic approach
OH
OOOHR
Chelation-Controlled Reduction: Stereoselective Formation of syn-1,3-Diols
Chemo and stereoselective epoxyde reduction
OH
OOHR
O
OHIodolactonization
(...)
![Page 30: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/30.jpg)
Statins side chain, Via IodolactonizationSubstarte controlled
O
OOONC
(a) Stanislav Ràdl,* Jan Stach and Josef Hajicek, Tetrahedron Letters, 43 (2002) 2087–2090(b) Butler, D. E.; Deering, C. F.; Millar, A.; Nanninga, T. N.; Roth, B. D. (Warner-Lambert Co.) US Patent 5,245,047.
OH OI
O
O
OONC
O
OONC
O
(i) BuLi/THF(ii) CO2 (iii) I2
(iv) p-TsOH, acetone, rt;
(v) KCN/DMSO, 40°C;
(vi) OsO4–NaIO4/dioxane–H2O; or (vii) O3; then (viii) Me2S;(ix) CrO3–H2SO4
acetone, 0°C
90%
75-80%
70%
OOI
OONC
91%
65%-70%
OH
OONC
O
X (x) mCPBA/CH2Cl2, rt;(xi) H5IO6/Et2O, rt;
86%60%
(xii) CrO3, H5IO6, acetone.
Cis-Racemate
![Page 31: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/31.jpg)
Reagent Controlled Iodolactonizations are rare…
R1 CO2H
R1 = para-substituted aryl groups
NH2
ICl (1 eq.)
(2 eq.)
-78 oCCH2Cl2
OOR1
I
approx. 5 - 25 % ee
O
R1
OH
R1 = aryl groups
N
R3
R2OH
X
(30 mol %)
CH2Cl2, NaHCO3 aq, I2, 0 oC OR1
I
O O O
I
R1+
yield = 37 - 93 % (combined, though typically 5-exo products are
heavily favoured))
approx. 6 - 28 % ee
Haas, J.; Piguel, S.; Wirth*, T. Org. Lett. 2002, 2, 297 – 300.
Wang, M.; Gao*, L. X.; Mai, W. P.; Xia, A. X.; Wang, F.; Zhang, S. B. J. Org. Chem. 2004, 69, 2874 – 2876.
![Page 32: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/32.jpg)
Reagent Controlled Iodolactonizations are rare…
2. I2, -78 oC, CH2Cl2
1. 30 mol % salen-Co, NCS. PhMe, rt, 30 min,
N N
t-Bu
t-Bu t-Bu
t-BuO OCo
R1
HO
R1 = alkyl groups
OR1
I
yield = 83 - 94 %approx. 67 - 90 % ee
Kang, S. H.; Lee, S. B.; Park, C. H. J. Am. Chem. Soc. 2003, 125, 15748 – 15749.
![Page 33: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/33.jpg)
Statins Family: Common side chain
R
O
OHO
OH
OOHOHR
1,3 syn diolAbsolute configuration
(3R, 5S)
Enzymatic and chemo-enzymatic approach
OH
OOOHR
Chelation-Controlled Reduction: Stereoselective Formation of syn-1,3-Diols
Chemo and stereoselective epoxyde reduction
OH
OOHR
O
OHIodolactonization
(...)
![Page 34: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/34.jpg)
OH
OH
C3 symmetryinternal plan of symmetry
HO OH
OHOH
OH
HO OH
OH
HO OH
Rh/CH2H2O
OTBDPS
TBDPSO OH
TBDPSiCl (2 eq)DMF Imidazole
PCC
OTBDPS
TBDPSO O
mCPBA
O
TBDPSO
TBDPSOO
1-EtOH/TFA2-PCC
OEt
OOPGOPG
O
Mixture of cis- cis and cis- trans
Statins side chain, Other methods…
O. Repic. K. Prasad, Org. Pro. R&D, 2001, 5, 519
![Page 35: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/35.jpg)
Statins Family: Common side chain
R
O
OHO
OH
OOHOHR
1,3 syn diolAbsolute configuration
(3R, 5S)
Enzymatic and chemo-enzymatic approach
OH
OOOHR
Chelation-Controlled Reduction: Stereoselective Formation of syn-1,3-Diols
Chemo and stereoselective epoxyde reduction
OH
OOHR
O
OHIodolactonization
(...)
![Page 36: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/36.jpg)
MAUREEN ROUHI, ‘CHIRAL CHEMISTRY’, C&EN News, June 14, 2004, Volume 82, Number 24, p. 47-62
‘Despite the unrelenting pace of research in catalytic asymmetric chemistry, relatively few catalytic
enantioselective processes are currently operated on a commercial scale.
Until more bio- and chemocatalytic chiral routes are developed that are robust and cost-effective for
large-scale production, the bulk of optically pure compounds will have to be prepared through traditional chemistry, including conventional
syntheses based on chiral substrates or stoichiometric chiral induction and separations, such
as chromatographic resolutions’.
MAUREEN ROUHI
Stereoselective synthesis vs. traditional chemistry
![Page 37: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/37.jpg)
Michael Muller, Angew. Chem. Int. Ed., 2005, 44, 362 –365
Statins side chain, Chemo-Enzymatic approach
DERA
After 15 h, product isolated in 96% yield (98.5%ee), 619 g.L-1d-1.
![Page 38: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/38.jpg)
Michael Muller, Angew. Chem. Int. Ed., 2005, 44, 362 –365
Statins side chain, Chemo-Enzymatic approach
![Page 39: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/39.jpg)
Statins side chain, Chemo-Enzymatic approach
R. Öhrlein*, G. Baisch, Adv. Synth. Catal., 2003, 345, 713 -715 (CIBA)
(α-Chymotrypsine-BioFac)
Highly scalable process (400g in one batch)
Cl O
OORO
![Page 40: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/40.jpg)
Statins side chain, Chemo-Enzymatic approach
R. Öhrlein*, G. Baisch, Adv. Synth. Catal., 2003, 345, 713 -715 (CIBA)
PLE: Pig liver esterase
‘This so called ‘aza’-W ittig reaction, whichproceeds via an imine intermediate is promoted by a
phosphine reagent and a weak, sterically hindered acid’.R. Öhrlein
Cl O
OORO
Cl OEt
OO O(CH2Cl)2, 0°C, ethylene, AlCl3
89%OEt
OO O
Cl OEt
OO OH
Cl
PLE, pH7, 76%
OEt
OO O
N3
1- BEt3, NaBH4, 91%2-Dimetoxypropane, H+, 99%3-NaN3, DMF, 94%, ee 98.1%, de 98.8%
O OMe O OMe
![Page 41: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/41.jpg)
Michael Muller, Angew. Chem. Int. Ed., 2005, 44, 362 –365
Statins side chain, Chemo-Enzymatic approach
DERA
![Page 42: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/42.jpg)
Statins side chain, Total- Enzymatic approach
~‘Absolute’ stereo control>99.9% ee, >96.6% de
(a) Junjie Liu, Che-Chang Hsu and Chi-Huey Wong* , Tetrahedron Letters, 45 (2004) 2439–2441. Scripps RI, La Jolla. 10 dec 2003 (Early work since 1994)(b) W. A. Greenberg*, A. Varvak, S. R. Hanson, K. Wong, H. Huang, P. Chen, and M. J. Burk*, PNAS, April 20, 2004 vol. 101 no. 16,5788–5793. Diversa Co.14 Nov. 2003
O
OOO
N3
![Page 43: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/43.jpg)
Statins side chain, Total -Enzymatic approach
(b) W. A. Greenberg*, A. Varvak, S. R. Hanson, K. Wong, H. Huang, P. Chen, and M. J. Burk*, PNAS, April 20, 2004 vol. 101 no. 16,5788–5793. Diversa Co.
O
OOO
N3
![Page 44: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/44.jpg)
Statins side chain, Direct Cross Aldol approach
XH H
O O+ 2
Asymmetic catalyst O
OH
OHX
Alan B. Northrup and David W. C. MacMillan*, J. Am. Chem. Soc. 2002, 124, 6798-6799
![Page 45: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/45.jpg)
Statins side chain, Direct Cross Aldol approach
Alan B. Northrup and David W. C. MacMillan*, J. Am. Chem. Soc. 2002, 124, 6798-6799
![Page 46: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/46.jpg)
Statins side chain, Direct Aldol approach
XH H
O O+ 2
Asymetic catalyst O
OH
OHX
Alan B. Northrup, Ian K. Mangion, Frank Hettche, and David W. C. MacMillan* ,Angew. Chem. Int. Ed. 2004, 43, 2152 –2154
![Page 47: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/47.jpg)
Statins side chain, Direct Aldol approach
Alan B. Northrup, Ian K. Mangion, Frank Hettche, and David W. C. MacMillan* ,Angew. Chem. Int. Ed. 2004, 43, 2152 –2154
![Page 48: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/48.jpg)
Statins side chain, Direct Aldol approach (…)
Review: S. Saito*, H. Yamamoto*, Acc. Chem. Res. 2004, 37, 570-579
![Page 49: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/49.jpg)
Statins side chain, Direct Aldol approach (…)
Review: S. Saito*, H. Yamamoto*, Acc. Chem. Res. 2004, 37, 570-579
![Page 50: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/50.jpg)
N
RO
R H
O
OH
Houk/ List Model for Proline-Catalyzed Asymmetric Intermolecular Aldol Reactions…
Bahmanyar, S.; Houk, K. N.; Martin, H. J.; List, B. J. Am. Chem. Soc. 2003, 125, 2475 – 2479.
![Page 51: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/51.jpg)
Review: S. Saito*, H. Yamamoto*, Acc. Chem. Res. 2004, 37, 570-579
Statins side chain, Direct Aldol approach (…)
![Page 52: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/52.jpg)
•Introduction and problematic
•Cholesterol biosynthesis (what can we learn from a biochemical process?)
•The missing members of the family
•Merck reduction of complexity of natural statins
•Synthetic Statins
• Exemple of industrial synthesis: Lescol
Statins Family: Cholesterol-Lowering Drugs
OUTLINE
![Page 53: Yassir EL-AZIZI Literature meeting A. Charette group 15 Feb. 2005](https://reader035.fdocuments.us/reader035/viewer/2022062521/5681685f550346895ddea890/html5/thumbnails/53.jpg)
The story of Lescol®
O. Repic. K. Prasad, Org. Pro. R&D, 2001, 5, 519
O
ONa
N
F
OH OH